Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich sold 5,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $141.71, for a total value of $708,550.00. Following the completion of the sale, the director now directly owns 35,649 shares of the company’s stock, valued at approximately $5,051,819.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ligand Pharmaceuticals Incorporated (LGND) traded down $1.40 on Friday, reaching $140.31. The company had a trading volume of 251,757 shares, compared to its average volume of 215,760. The firm has a market capitalization of $2,930.00, a PE ratio of 109.07, a price-to-earnings-growth ratio of 2.24 and a beta of 0.93. Ligand Pharmaceuticals Incorporated has a 52-week low of $95.08 and a 52-week high of $149.31. The company has a current ratio of 0.97, a quick ratio of 0.95 and a debt-to-equity ratio of 0.05.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.32. The firm had revenue of $33.38 million during the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The business’s revenue for the quarter was up 54.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.62 earnings per share. research analysts forecast that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.
Several analysts have recently commented on LGND shares. TheStreet raised Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $157.00 target price on shares of Ligand Pharmaceuticals in a research report on Thursday, October 5th. Roth Capital raised their target price on Ligand Pharmaceuticals from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Craig Hallum reaffirmed a “buy” rating and issued a $170.00 target price (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday. Finally, Zacks Investment Research cut Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $148.83.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.